OCT 01, 2015 12:00 PM PDT

Keynote Presentation (during an actual infusion!): Patient #1 - Pioneering Immunotherapy and Finding The Best, Right Treatment for Stage IV Melanoma

Speakers
  • Patient, Survivor, Advocate, and Author of the "Patient #1" blog
    Biography
      T.J. Sharpe is sharing his fight against Stage 4 Melanoma in his weekly Patient #1 blog on www.Philly.com/Patient1. A South Jersey native and Bishop Eustace and Carnegie Mellon University graduate, he currently lives in Fort Lauderdale, FL with his wife Jennifer and children Josie and Tommy. He was Patient #1 in a clinical trial at Moffitt Cancer Center in Tampa as the first person worldwide to use this sequence of treatments to fight melanoma, and is currently in a second clinical trial at Holy Cross Hospital in Fort Lauderdale receiving Merck's anti-PD-1 drug pembrolizumab

    Abstract:

    Stage IV melanoma carried a 24 month life expectancy three short years ago. That is what T.J. Sharpe’s first oncologist told him he was facing, after a visit to the ER for a fever turned into a metastatic melanoma diagnosis. His quest to overcome these long odds and beat cancer has taken him through two clinical trials, four immunotherapies, and six surgeries – all while sharing the highs and lows of cancer treatment on www.Philly.com. Fortunately, those three years have seen a great advance in melanoma treatments, one Mr. Sharpe has witnessed first-hand and shared with the world through his blog, advocacy speaking, and participation in conferences for cancer, biotechnology, and clinical trials. Being a husband and father (second child Tommy was born a mere four weeks before the diagnosis), his story combines the medicinal side of the current immunotherapy treatments being presented at the Labroots Cancer Research and Oncology event, alongside how these treatments affect everyday life. It also gives medical professionals, researchers, caretakers, and other cancer patients insight into getting the best, right care and how to overcome the avalanche of information and decisions that a cancer diagnosis brings. While he is sharing his patient perspective, T.J. will receive his 42nd dose of pembrolizumab, as part of the second clinical trial.


    Show Resources
    You May Also Like
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...